Controlled delivery of TLR3 agonists in structural polymeric devices
First Claim
Patent Images
1. A device comprising a polymeric structure composition, a tumor antigen, and a TLR3 agonist, wherein said TLR3 agonist comprises condensed polyinosine-polycytidylic acid (poly I:
- C) cationic nanoparticles, said condensed poly I;
C cationic nanoparticles being formed by mixing said poly I;
C with a polycation comprising positively charged amine groups at a charge ratio resulting in positively charged condensates and an average particle size of 98-545 nm.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents.
145 Citations
27 Claims
-
1. A device comprising a polymeric structure composition, a tumor antigen, and a TLR3 agonist, wherein said TLR3 agonist comprises condensed polyinosine-polycytidylic acid (poly I:
- C) cationic nanoparticles, said condensed poly I;
C cationic nanoparticles being formed by mixing said poly I;
C with a polycation comprising positively charged amine groups at a charge ratio resulting in positively charged condensates and an average particle size of 98-545 nm. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
- C) cationic nanoparticles, said condensed poly I;
Specification